Since HER2-positive breast cancer has a poor prognosis without targeted therapy [35, 36], there is an urgent need for implementation of HER2 diagnostic services as well as directed targeted therapy, and there are now ongoing training and capacity-building in the Pathology laboratory in TASH to implement ISH for HER2 verification. The gene discussed is ERBB2; the disease is breast carcinoma.